DSpace university logo mark
Advanced Search
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > University Hospital > Articles in academic journal >

Decrement of serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) patients achieving remission after 6 months of etanercept treatment: Comparison with CRP, IgM-RF, MMP-3 and anti-CCP Ab.


File Description SizeFormat
JBS77_418.pdf534.25 kBAdobe PDFView/Open

Title: Decrement of serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) patients achieving remission after 6 months of etanercept treatment: Comparison with CRP, IgM-RF, MMP-3 and anti-CCP Ab.
Authors: Kawashiri, Shin-Ya / Kawakami, Atsushi / Ueki, Yukitaka / Imazato, Takahiro / Iwamoto, Naoki / Fujikawa, Keita / Aramaki, Toshiyuki / Tamai, Mami / Nakamura, Hideki / Origuchi, Tomoki / Ida, Hiroaki / Eguchi, Katsumi
Issue Date: Oct-2010
Publisher: Elsevier Masson SAS
Citation: Joint Bone Spine, 77(5), pp.418-420; 2010
Abstract: OBJECTIVE: The aim of this study was to evaluate whether serum COMP can estimate the therapeutic response of RA after 6 months of treatment with etanercept. METHODS: Forty-five RA patients receiving 25mg of etanercept twice a week for 6 months were registered in this prospective observational study. Clinical response to the therapy was evaluated by DAS 28. Laboratory variables- COMP, CRP, ESR, IgM-RF, MMP-3, and anti-CCP Ab -were assessed at baseline and after 6 months of treatment. We assessed the correlations between serum COMP and other variables and whether serum COMP is associated with DAS28 remission. RESULTS: Serum COMP correlated with DAS28-ESR (p<0.05, r=0.40) at baseline. At 6 months of etanercept treatment, 10 patients entered remission (DAS28-ESR<2.6) whereas the other 35 patients did not (DAS28-ESR>2.6). The decrement of serum COMP at 6 months was significant in the remission group (N=10) but not in the non-remission group (N=35). On the other hand, CRP, ESR and MMP-3 decreased at 6 months regardless of remission status. IgM-RF titer as well as anti-CCP Ab titer did not differ at 6 months. CONCLUSIONS: Serum COMP at baseline reflects clinical disease activity of RA. Serum COMP is a valuable serologic marker to identify the subset of RA patients achieving remission during treatment with etanercept.
Keywords: Cartilage oligomeric matrix protein / Etanercept / Rheumatoid arthritis
URI: http://hdl.handle.net/10069/24324
ISSN: 1297319X
DOI: 10.1016/j.jbspin.2010.01.016
PubMed ID: 20864374
Rights: Copyright © 2010 Published by Elsevier Masson SAS
Type: Journal Article
Text Version: author
Appears in Collections:Articles in academic journal

Citable URI : http://hdl.handle.net/10069/24324

All items in NAOSITE are protected by copyright, with all rights reserved.

 

Valid XHTML 1.0! Copyright © 2006-2015 Nagasaki University Library - Feedback Powerd by DSpace